drugset / Trial / NCT00088478

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

NCT00088478

Phase 3 Completed 402 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

Key objectives of this clinical study are to: * Determine how well intramuscular (IM) olanzapine depot works compared to placebo * Evaluate the safety and tolerability of IM olanzapine depot compared to placebo * Evaluate different doses of IM olanzapine depot compared to placebo to identify the best dose(s).

Timeline

Start
2004-06
Primary completion
Completion
2005-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 210 mg Intramuscular
Subject Olanzapine Small molecule 300 mg Intramuscular
Subject Olanzapine Small molecule 405 mg Intramuscular

Indications